No Data
A Quick Look at Today's Ratings for Erasca(ERAS.US), With a Forecast Between $4 to $6
Erasca's Promising Developments and Positive Outlook Justify Buy Rating
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Bullish Erasca Insiders Loaded Up On US$3.97m Of Stock
No Data
No Data